PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
CMB International Global Markets  Equity Research  Company Update
WuXi AppTec (603259 CH)
Earnings recovery underway
WuXi AppTec reported 3Q24 revenue of RMB1046bn slightly down 20% YoY
and attributable adjusted non-IFRS net profit of RMB297bn down 32% YoY
Total non-COVID revenue and non-COVID Chemistry revenue growth rebounded
to 146% YoY and 264% YoY respectively in 3Q24 Despite the challenging
geopolitical environment mgmt reiterated its revenue guidance of RMB383-
405bn for 2024 indicating 27%86% YoY non-COVID revenue growth
IFRS net profit margin consistent with the levels achieved in 2023
AppTecs backlog climbed to RMB4382bn representing a YoY increase of
353% maintaining the encouraging momentum of 332% YoY growth
growth signified the enduring trust that global clients place in WuXi AppTecs
high-quality and efficient services This is further evidenced by a robust 231%
a notable acceleration from the 119% growth observed in 1H24
Management has indicated that 80% of the backlog is expected to convert
into revenue within the next 12 to 18 months providing strong earnings
visibility for WuXi AppTec in 4Q24 and throughout 2025 in our view
 TIDES continues to exhibit strong growth TIDES revenue grew by 710%
YoY in 9M24 with the growth accelerating to 986% YoY in 3Q24 The TIDES
backlog as of 3Q24 saw a substantial YoY increase of 196% In Jan 2024
WuXi AppTec expanded its peptide production capacity from 10k liters to 32k
liters with plans to expand to 41k liters by the end of 2024 and further to 100k
liters by 2025 This ambitious expansion underscores WuXi AppTecs
services positioning TIDES as the strongest growth driver for the Company
through 2026
the medium term In our in-depth report published on 21 Oct 2024 we
and India engaged in API and chemical CDMO services The findings reveal
scale and capacity Specifically most Indian peers primarily offer bulk and
specialty APIs with limited capabilities in supporting innovative drugs RD
Meanwhile European firms despite having an established pharmaceutical
manufacturing base with several well-known chemical CDMOs tend to focus
more on formulation instead of API Their manufacturing sites primarily
 Maintain BUY Factoring in the positive trend of customer demand we lift our
TP from RMB6772 to RMB7237 (based on a 10-year DCF model with
WACC of 942% and terminal growth of 20%) We forecast revenue to grow
by -39% 119% 155% YoY in 2024E 25E 26E respectively
(Previous TP
UpDownside
Jill WU CFA
Benchen HUANG CFA
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued Shares (mn)
Source FactSet
Shareholding Structure
Ge Li and concerted parties
Source Company report
Source FactSet
12-mth Price Performance
Source FactSet
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
Adjusted net profit (RMB m
YoY growth (%)
EPS (Adjusted) (RMB)
Consensus EPS (RMB)
PE (Adjusted) (x)
Source Company data Bloomberg CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 Earnings revision
Non-IFRS net profit
Non-IFRS EPS (RMB)
Source Company data CMBIGM estimates
Figure 2 CMBIGM estimates vs consensus
Non-IFRS net profit
Non-IFRS EPS (RMB)
Source Company data Bloomberg CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 3 Valuation on risk-adjusted DCF valuation
DCF Valuation (in Rmb mn)
EBIT(1-tax rate)
- Change in working capital
Target Debt to Asset ratio
Effective Corporate Tax Rate
PV of terminal value (RMB mn)
Total PV (RMB mn)
Net debt (RMB mn)
Equity value (RMB mn)
 of shares (mn)
Price per share (RMB per share)
Source CMBIGM estimates
Figure 4 Sensitivity analysis of DCF model
Source CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
RD expense
Gainloss on financial assets at FVTPL
Investment gainloss
Pre-tax profit
YE 31 Dec (RMB mn)
Cash  equivalents
Financial assets at FVTPL
Non-current assets
Investment in JVs  assos
Financial assets at FVTPL
Other non-current assets
Short-term borrowings
Other current liabilities
Non-current liabilities
Long-term borrowings
Obligations under finance leases
Other non-current liabilities
Total shareholders equity
Total equity and liabilities
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
Profit before taxation
Depreciation  amortization
Change in working capital
Net cash from operations
Acquisition of subsidiaries investments
Net proceeds from disposal of short-term
Net cash from investing
Proceeds from share issues
Net cash from financing
Cash at the beginning of the year
Cash at the end of the year
Adj net profit
Adj net profit margin
Return on equity (ROE)
GEARINGLIQUIDITYACTIVITIES
Net debt to equity (x)
Current ratio (x)
Receivable turnover days
Inventory turnover days
Payable turnover days
PE (adjusted)
Div yield (%)
Source Company data CMBIGM estimates Note The calculation of net cash includes financial assets
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities or issuer
that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer and (2)
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures
Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report (2) will
deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve as an officer of any of the Hong
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIGM
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Global Markets Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Global Markets Limited (CMBIGM) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned
subsidiary of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIGM
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in the
report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIGM solely for the purpose of supplying information to the clients of CMBIGM
or its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIGM nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
the information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIGM may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with
and CMBIGM will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIGM
For recipients of this document in the United States
CMBIGM is not a registered broker-dealer in the United States  As a result CMBIGM is not subject to US rules regarding the preparation of research reports
and the independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or qualified
as a research analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA Rules
intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report is
intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange Act of
1934 as amended and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this report
by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person Any US recipient of this report wishing to
effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as defined
in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced by its
respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations
Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined in the Securities
and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law
Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report